BTK and B-cell chronic lymphocytic leukemia: Although results from a direct PFS comparison between TP53 deficient and non-deficient cases are not available yet, data from the SEQUOIA and ALPINE trials testing the second-generation covalent BTK inhibitor zanubrutinib in first-line and in relapsed/refractory CLL further support this hypothesis (27, 28).